Sheet <u>1 of 3</u>

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P51365	SERIAL NO. 10/518,654	
INFORMATION D	ISCLOSURE STATEMENT	APPLICANT		
ВҮ	APPLICANT	Brooks et al.		
(1100 00000	al abanta if wasaasawa	FILING DATE	GROUP	
(Use severa	al sheets if necessary)	December 16, 2004	1626	

APPLICANTS CO-PENDING U.S. PATENT APPLICATIONS/ U.S. PUBS.

APPLICANTS CO-PENDING U.S. PATENT APPLICATIONS/ U.S. PUBS.					
Examiner		Document Number	Date	Name	Filing Date
Initial					lf
					Appropriat e
		US2004/0220250A1 (U.S. Appln.	Pub. Date:	Oh	e
		Ser. No. 10/345,746, Filed: 1/16/03)	11/4/04	On	
		WO99/24017 Pub. Date: 5/20/99	11/4/04		
		"Novel Oral Dosage Form For Carvedilol"- ABN			
		US2004/0186158A1 (U.S. Appln.	Pub. Date:	Oh	
		Ser. No. 10/491,195, Filed 3/31/04)	9/23/04	On	
		WO03/028649 Pub. Date: 4/10/03	9/23/04		
		"Novel Composition of Carvedilol" – ABN			
		US2005/0009897A1 (U.S. Appln.	Pub. Date:	Anderson et al.	
		Ser. No. 10/473,667 Filed: 9/3/04)	1/13/05	Anderson et al.	
		PCT/US02/10299 Filed: 4/2/02	1/15/05		
		WO02/078692 Pub. Date: 10/10/02			
		"Method of Treatment" - ABN			
		US2004/0019096A1 (U.S. Appln.	Pub. Date:	Oh et al.	
		Ser. No. 10/415,671 Filed 4/23/03)	1/29/04	On Ct all.	
		PCT/US01/50872 Filed 10/23/01	1,25,04		
		WO02/065834 Pub. Date: 8/29/02			
		"Novel Formulations of Carvedilol"			
		US2002/0107279A1 (U.S. Appln.	Pub. Date:	Barone et al.	
		Ser. No. 10/102,514 Filed: 3/20/02)	8/08/02	Barone et an.	
		PCT/US93/11598 Filed: 12/01/92	0,00,02		
		"Antioxidant Neuroprotective Use of and			
		Method of Treatment" – ABN	3-17-17 x 11-17	7-A 190 h	
		US20040152756A1 (U.S. Appln.	Pub. Date:	Chen et al.	
		Ser. No. 10/483,217 Filed 1/8/04)	8/5/2004		
		PCT/US 2002/2237 Filed: 7/13/01			
		WO03/005970 Pub. Date: 1/23/03	8		l l
		"Carvedilol Polymorph" – ABN		2000	
		U.S. Appln. Ser. No. 10/513,234	Pub. Date:	Oh	
		Filed: 5/03/02	11/13/03	.14	
	7 0	PCT/US03/14021 Filed: 5/3/02		7.0	
		WO03/092626 Pub. Date: 11/13/03			N (
		"Carvedilol Pharmasolve Solvate"			
		U.S. Appln. Ser. No. 10/513,235	Pub. Date:	Oh et al.	
		Filed: 11/2/2004	11/13/03		
		PCT/US03/14020 Filed: 5/3/02			
		WO03/092626 Pub. Date: 11/13/03			
		"Carvedilol Formulations"		-	_
		U.S. Appln. Ser. No. 10/518,206	Pub. Date: 1/8/04	Chen et al.	
		Filed: 12/16/2004			
		PCT/US03/20346 Filed: 6/27/02			
		WO04/002472 Pub. Date: 1/8/04			
		"Carvedilol Hydrobromide"	717	01 1	
		US20050148779A1 (U.S. Appln.	Pub. Date:	Oh et al.	
		Ser. No. 10/512,628 Filed: 10/26/04)	7/7/2005		
		PCT/US00/17832 Filed: 4/30/02			
		WO03/092622 Pub. Date: 11/13/03			
		"Carvedilol Monocitrate Monohydrate"	D 1 D 4 6/0/07	D 1 1 1	
		U.S. Appln. Ser. No. 10/997,230	Pub. Date: 6/9/05	Brook et al.	
		Filed: 11/24/04			
		PCT/US04/039528 Filed: 11/24/04			
		WO05/051383 Pub. Date: 6/9/05			
		"Carvedilol Salts, Corresponding Compositions,			
		Methods of Treatment"			

PCT/US04/039614 Filed: 11/24/04	Pub. Date:	Castan et al.	
WO05/051322 Pub. Date: 6/9/05	8/11/05		
Carvedilol Pharmaceutical Compositions,			
Controlled Release Formulations, and Treatment			
or Delivery Methods			
US20050169994A1 (U.S. Appln.	Pub. Date: 8/4/05	Burke et al.	
Ser. No. 10/996,904 Filed: 11/24/04)			
PCT/US04/039677 Filed: 11/24/04			
WO05/051325 Pub. Date: 6/9/05			
Carvedilol Pharmaceutical Compositions,			
Controlled Release Formulations, and Treatment			
or Delivery Methods			
U.S. Appln. Ser. No. 11/137,261	Filed: 5/25/05	Burke et al.	
CIP 10/996,904 Filed: 11/24/04			

## **U.S. PATENT DOCUMENTS**

Examiner	Document Number	Date	Name	Class	Subclass	Filing Date
Initial	Boodinent (4dinse)	Date	Name	0,033	Cubolado	If Appropriate
	4,503,067	3/5/85	Wiedemann et al.			
	4,985,454	1/15/91	Leinert			
	5,071,868	12/10/91	Leinert			
	5,308,862	5/3/95	Ohlstein			
	5,393,772	2/28/95	Yue et al.			
	5,405,863	4/11/95	Barone et al.			
	5,453,436	9/26/95	Ohlstein			
	5,643,939	7/1/97	Ohlstein			
	5,760,069	6/2/98	Lukas-Laskey et al			
	5,902,821	5/11/99	Lukas-Laskey et al			
	6,096,777	8/1/00	Feuerstein et al.			
	6,214,854	4/10/01	Wang et al.			
	6,358,990	3/19/02	Howlett et al.			
	6,403,579	6/11/02	Heller			
	6,515,010	2/4/03	Franchini et al.			
	6,699,997	3/2/04	Hildesheim et al.			
	6,852,337	2/8/05	Gabel et al.			
	7,056,942	6/6/06	Hildesheim et al.			
	7,126,008	10/24/06	Hildesheim et al.			
	US 2001/0036959	11/1/01	Gabel et al.			
	US 2001/0036960	11/1/01	Decker et al.			
	US 2002/0143045	10/3/02	Hildesheim et al.			
	US 2002/0052367	5/2/02	Heller			
	US 2002/0068740	6/6/02	Mylari			_
	US 2002/0099013	7/25/02	Piccariello et al.			
	US 2002/0099046	7/25/02	Scott			
	US 2002/0115655	8/22/02	Mehanna et al.			
	US 2002/0169199	11/14/02	Gruber et al.			
	US 2003/0004205	1/2/03	Gabel et al.			
	US 2003/0004206	1/2/03	Decker et al.			
	US 2003/0035836	2/20/03	Shanghvi et al.			
	US 2003/0036559	2/20/03	Beyer et al.			
	US 2003/0166702	9/4/03	Kor et al.			
	US 2003/0050301	3/13/03	Mylari			
	US 2003/0054041	3/20/03	Lemmens et al.			

Document Number	Date	Country	Class	Subclas	<u>Translation</u>	
		-		s	Yes	No
WO98/02157	1/22/98	WIPO				
WO99/05105 A1	2/4/99	WIPO				
WO99/52526	10/21/99	WIPO				
WO00/004902	2/3/00	WIPO				
WO00/032174	6/8/00	WIPO				
WO01/74356	10/11/01	WIPO				
WO01/87837 A1	11/22/01	WIPO				
WO02/00216 A1	1/3/02	WIPO				
WO02/092078	11/21/02	WIPO				
WO03/007962	1/30/03	WIPO				
WO03/024426	3/27/03	WIPO				
WO03/024429	03/27/03	WIPO				
WO03/028645	4/10/03	WIPO				
WO03/028718	4/10/03	WIPO				
WO04/009120	1/29/04	WIPO				
 WO04/016249	2/26/04	WIPO				
WO04/041252	5/21/04	WIPO				
WO04/056336	7/8/04	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER		DATE CONSIDERED
EVANABLE	). I (4).	al if situation considered, whether or not situation is in conformance with MDED 600. Draw line through situation if not

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

n:\gch\apps\pu cases\pu60579a\pto 1449 form.doc